Evidence map›Paper›PMID 30323615›Full record

ArticleOncoTargets and therapy2018

Elemene treatment for NSCLC with multiple CNS metastases: a case report and literature review.

Yushan Han, Xia Zhang, Yishan Lu, Yan Dong, Hong Fu, Bin Zhang, Yajie Gao

Open access · goldAbstract readCase Reports
In one paragraph

Article in OncoTargets and therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Yushan HanDepartment of Oncology, The First Affiliated Hospital of Dalian Medical University, Dalian, People's Republic of China, zhangbin_dlmu@163.com; gaoyajie100@126.com.
Xia ZhangDepartment of Oncology, The Fifth People's Hospital of Dalian, Dalian, People's Republic of China.
Yishan LuQueen Mary University of London, London, UK.
Yan DongDepartment of Oncology, The First Affiliated Hospital of Dalian Medical University, Dalian, People's Republic of China, zhangbin_dlmu@163.com; gaoyajie100@126.com.
Hong FuDepartment of Oncology, The First Affiliated Hospital of Dalian Medical University, Dalian, People's Republic of China, zhangbin_dlmu@163.com; gaoyajie100@126.com.
Bin ZhangDepartment of Oncology, The First Affiliated Hospital of Dalian Medical University, Dalian, People's Republic of China, zhangbin_dlmu@163.com; gaoyajie100@126.com.
Yajie GaoDepartment of Oncology, The First Affiliated Hospital of Dalian Medical University, Dalian, People's Republic of China, zhangbin_dlmu@163.com; gaoyajie100@126.com.
Dalian Medical University · CNFirst Affiliated Hospital of Dalian Medical University · CNNanchang University · CNThe Third People's Hospital of Dalian City · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CNS metastases are common in patients with non-small-cell lung cancer (NSCLC) and is associated with poor prognosis. In NSCLC patients with EGFR mutations, and ALK fusion oncogene, chemotherapy is ineffective; however, targeted and pulse therapies may be used as alternative treatment options. Elemene can cross the blood-brain barrier and enter the brain tissue. In this paper, treatment consisting of elemene injections in a case of NSCLC with brain metastases, spinal metastases and a possible complication of leptomeningeal metastases is reported, and the efficacy of elemene in treating NSCLC with CNS metastases was investigated.

Indexed as

CNS metastaseselemeneNSCLC

Identifiers

PMID30323615
PMCPMC6174310
OpenAlexW2893564168

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.